Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03737461Phase 2Active Not Recruiting

Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive

Role: collaborator

NCT03673748Phase 2Recruiting

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Role: collaborator

NCT03884569Not Yet Recruiting

Cultivated Limbal Epithelial Transplantation (CLET) for Limbal Stem Cell Deficiency (LSCD)

Role: collaborator

NCT01860417Phase 1Completed

Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)

Role: collaborator

NCT04361942Phase 2Completed

Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells

Role: collaborator

NCT01389661Phase 1Completed

Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)

Role: collaborator

All 6 trials loaded